Nepal | November 24, 2020

Oxford and AstraZeneca resume coronavirus vaccine trial

Associated Press
Share Now:

ONDON (AP) — Oxford University announced Saturday it was resuming a trial for a coronavirus vaccine it is developing with pharmaceutical company AstraZeneca, a move that comes days after the study was suspended following a reported side-effect in a U.K. patient.

In a statement, the university confirmed the restart across all of its U.K. clinical trial sites after regulators gave the go-ahead following the pause on Sunday.

“The independent review process has concluded and following the recommendations of both the independent safety review committee and the U.K. regulator, the MHRA, the trials will recommence in the U.K.,” it said.

The vaccine being developed by Oxford and AstraZeneca is widely perceived to be one of the strongest contenders among the dozens of coronavirus vaccines in various stages of testing around the world.

British Health Secretary Matt Hancock welcomed the restart, saying in a tweet that it was “good news for everyone” that the trial is “back up and running.”

The university said in large trials such as this “it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety.”

It said globally some 18,000 people have received its vaccine so far. Volunteers from some of the worst affected countries — Britain, Brazil, South Africa and the U.S. — are taking part in the trial.

Brazil’s health regulator Anvisa on Saturday said it had approved the resumption of tests of the “Oxford vaccine” in the South American country after receiving official information from AstraZeneca.

Although Oxford would not disclose information about the patient’s illness due to participant confidentiality, an AstraZeneca spokesman said earlier this week that a woman had developed severe neurological symptoms that prompted the pause. Specifically, the woman is said to have developed symptoms consistent with transverse myelitis, a rare inflammation of the spinal cord.

The university insisted that it is “committed to the safety of our participants and the highest standards of conduct in our studies and will continue to monitor safety closely.”

Pauses in drug trials are commonplace and the temporary hold led to a sharp fall in AstraZeneca’s share price following the announcement Tuesday.

The Oxford-AstraZeneca study had been previously stopped in July for several days after a participant developed neurological symptoms that turned out to be an undiagnosed case of multiple sclerosis that researchers said was unrelated to the vaccine.

During the third and final stage of testing, researchers look for any signs of possible side effects that may have gone undetected in earlier patient research. Because of their large size, the studies are considered the most important study phase for picking up less common side effects and establishing safety. The trials also assess effectiveness by tracking who gets sick and who doesn’t between patients getting the vaccine and those receiving a dummy shot.

Dr. Charlotte Summers, a lecturer in intensive care medicine at the University of Cambridge, said the pause was a sign that the Oxford team was putting safety issues first, but that it led to “much unhelpful speculation.”

“To tackle the global COVID-19 pandemic, we need to develop vaccines and therapies that people feel comfortable using, therefore it is vital to maintaining public trust that we stick to the evidence and do not draw conclusions before information is available,” she said.

Scientists and others around the world, including experts at the World Health Organization, have sought to keep a lid on expectations of an imminent breakthrough for coronavirus vaccines, stressing that vaccine trials are rarely straightforward.

Italy’s health minister, Roberto Speranza, welcomed the resumption of the vaccine trial, but warned that prudence was still necessary.

“Science is at work to give the world efficient and secure treatments and vaccines,” he said. “In the meantime, the key continues to be our behavior.”

Italy, which was ground zero for Europe’s outbreak, is one of the main countries investing in the AstraZeneca vaccine.

Two other vaccines are in huge, final-stage tests in the United States, one made by Moderna Inc. and the other by Pfizer and Germany’s BioNTech.

Follow The Himalayan Times on Twitter and Facebook

Recommended Stories:

More from The Himalayan Times:

Street children

Street children free nation drive picks up pace

KATHMANDU, NOVEMBER 22 The government’s campaign to achieve street children free status is gaining momentum with the implementation of related programmes. So far, 574 street children have been rescued and rehabilitated from various parts of the country. Of them, 465 are boys and 109 are girl Read More...

Closure of schools pushing students into drug addiction

RAUTAHAT, NOVEMBER 22 More school going students have started taking drugs after schools shut down for more than seven months following the outbreak of coronavirus in Rautahat. Locals say school students have fallen prey to drugs as schools have remained closed due to the lockdown imposed to c Read More...

Bajura remote areas linked to national grid

BAJURA, NOVEMBER 22 Far-flung areas of Bajura have been connected to the national transmission line for power supply for the first time. Nepal Electricity Authority, Bajura, Distribution Centre Chief Mahesh Chandra Bhatta said the district was connected to the national grid and electricity Read More...

NCP leader Bhim Rawal

NCP will stay intact, says Rawal

DHANGADI, NOVEMBER 22 Ruling Nepal Communist Party Sudurpaschim Province Incharge Bhim Rawal today said that the rift seen between the two party chairs would not lead to a split in the party. Speaking at a press meet held by Press Organisation, Kailali, in Dhangadi, Rawal said, “The NCP is n Read More...

DoCSCP takes action against 315 firms

KATHMANDU, NOVEMBER 22 The Department of Commerce, Supplies and Consumer Protection (DoCSCP) has taken action against a total of 315 firms in the first four months of the current fiscal year. In the review period, the department inspected a total of 1,071 firms of which 315 firms that tried to Read More...

Nepal Investment Bank, Durbar Marga

Mountain Energy Nepal appoints NIBL Ace Capital Ltd

KATHMANDU: Mountain Energy Nepal Ltd (MENL) has appointed NIBL Ace Capital Ltd as its share registrar. Mountain Energy Nepal is a limited company incorporated in Nepal under the Companies Act, 2053 and has its registered office in Dillibazar, Kathmandu. It was established with an objective to Read More...

Good Bricks System

KATHMANDU: Good Bricks System by InnoCSR, a South Korean company, has introduced responsible and sustainable impact technology brick solutions in Nepal. Using a proven technology, the leading South Korean company says its bricks are stronger and last longer. With a $125,000 grant from ADB Venture Read More...

‘Expand tax base, control tax leakage to increase revenue’

KATHMANDU, NOVEMBER 22 Finance Minister Bishnu Prasad Poudel has said that it is necessary to expand the tax base and also control tax leakage in order to increase the share of internal revenue in overall revenue structure. Speaking at the inauguration programme of the Inland Revenue Office in Read More...